Project Grant R01CA307266
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $687K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Institutes of Health National Cancer Institute awarded New York University $695,852 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate T cell circuits in the lymphatic system during melanoma progression. The project examines how stem-like memory CD8+ T cells in tumor-draining lymph nodes support anti-tumor immune surveillance and influence response to immunotherapy in melanoma patients. The research leverages expertise in lymphatic biology and new...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $752,808 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate clonal hematopoiesis as a mechanism of therapeutic resistance in anaplastic thyroid cancer. The research examines how clonal hematopoiesis—the age-related expansion of mutant hematopoietic stem and progenitor cells—drives resistance to BRAF-MEK inhibitor therapy in anaplastic thyroid cancer patients. The project...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Yale University $610,637 in project grant funding on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer and optimize drug delivery platforms for locoregional treatment of advanced melanoma. Yale will develop bioadhesive and non-adhesive biodegradable nanoparticles engineered to deliver cytotoxic and immune conditioning agents selectively to tumor cells, the tumor microenvironment, and tumor-draining lymph nodes. The research...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...